Pneumococcal Disease after pneumococcal vaccine 13-valent at the National Institute of Child Health during the period 2017-2020
PDF (Español (España))

Keywords

Streptococcus pneumoniae
Pneumococcal Vaccines
Child
Peru

How to Cite

1.
Marin Portocarrero JG, Quispe Sánchez AR, Charca Rodríguez F de M, Atamari Anahui N. Pneumococcal Disease after pneumococcal vaccine 13-valent at the National Institute of Child Health during the period 2017-2020. Andes pediatr [Internet]. 2023 Jun. 7 [cited 2025 Oct. 22];94(7):31-2. Available from: https://andespediatrica.cl/index.php/rchped/article/view/4768

Abstract

Introduction: Invasive Pneumococcal disease (IPD) is still a disease that is reported in Latin American countries. 

Objetive: To describe the clinical characteristics, serotypes, and antibiotic susceptibility in patients with IPD in a pediatric hospital in Peru. 

Material and Method: A descriptive and retrospective study was performed with data from patients under 18 years of age with IPD hospitalized between 2017 and 2020 at Instituto Nacional de Salud del Niño-Breña (Lima, Peru). Clinical variables, vaccination schedule, antibiotic susceptibility and isolated serotypes were described. 

Results: 29 patients were included. The median age was 1.9 years (range 2 months to 8 years). 51.7% were female and the most frequent clinical form of IPD was bacteremia in 18 (62.1%) patients. 65.5% had the complete vaccination schedule. 82.8% of the germ isolation was from blood. Antibiotic resistance was more frequent to erythromycin 55.2% and penicillin 24.1%. The registered serotypes were 6C, 19A, 23A, and 24F. One patient died for meningitis. 

Conclusions: IPD was more frequent from 1 to 5 years and in the clinical form of bacteremia. Five serotypes reported in previous studies with resistance to penicillin and erythromycin were found.

PDF (Español (España))

Los contenidos publicados en esta revista están protegidos bajo una Licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esto significa que cualquier persona es libre de compartir,  usar y construir a partir de este artículo, incluso con fines comerciales, siempre que se otorgue el crédito apropiado al autor original, se proporcione un enlace a la licencia, se indique el nombre y edición de la Revista.

Esta licencia no impone restricciones adicionales, lo que garantiza la libre circulación y reutilización del conocimiento con respeto y transparencia hacia los derechos de los autores.  (Véase El efecto del acceso abierto).